In this study, we used the data from TCGA-BRCA dataset and GEO database, constructed a risk signature based on four drug resistance-related genes and developed a nomogram to predict the survival of patients with stage I-III in ER+ and HER2- breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.